Page 68 - Read Online

Page 10 of 12 Ma et al. Hepatoma Res 2019;5:8 I http://dx.doi.org/10.20517/2394-5079.2018.104

7. Kawai-Kitahata F, Asahina Y, Tanaka S, Kakinuma S, Murakawa M, et al. Comprehensive analyses of mutations and hepatitis B virus
integration in hepatocellular carcinoma with clinicopathological features. J Gastroenterol 2016;51:473-86.
8. Totoki Y, Tatsuno K, Covington KR, Ueda H, Creighton CJ, et al. Trans-ancestry mutational landscape of hepatocellular carcinoma
genomes. Nat Genet 2014;46:1267-73.
9. Liu L, Lai S, Andrews LG, Tollefsbol TO. Genetic and epigenetic modulation of telomerase activity in development and disease. Gene
2004;340:1-10.
10. Lendvay TS, Morris DK, Sah J, Balasubramanian B, Lundblad V. Senescence mutants of Saccharomyces cerevisiae with a defect in
telomere replication identify three additional EST genes. Genetics 1996;144:1399-412.
11. Lingner J, Cech TR. Purification of telomerase from Euplotes aediculatus: requirement of a primer 3’ overhang. Proc Natl Acad Sci U
S A 1996;93:10712-7.
12. Cukusic A, Skrobot Vidacek N, Sopta M, Rubelj I. Telomerase regulation at the crossroads of cell fate. Cytogenet Genome Res
2008;122:263-72.
13. Pestana A, Vinagre J, Sobrinho-Simoes M, Soares P. TERT biology and function in cancer: beyond immortalisation. J Mol Endocrinol
2017;58:R129-R46.
14. Low KC, Tergaonkar V. Telomerase: central regulator of all of the hallmarks of cancer. Trends Biochem Sci 2013;38:426-34.
15. Liu T, Yuan X, Xu D. Cancer-specific telomerase reverse transcriptase (TERT) promoter mutations: biological and clinical
implications. Genes (Basel) 2016;7:E38.
16. Daniel M, Peek GW, Tollefsbol TO. Regulation of the human catalytic subunit of telomerase (hTERT). Gene 2012;498:135-46.
17. Poole JC, Andrews LG, Tollefsbol TO. Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene
2001;269:1-12.
18. Greenberg RA, O’Hagan RC, Deng H, Xiao Q, Hann SR, et al. Telomerase reverse transcriptase gene is a direct target of c-Myc but is
not functionally equivalent in cellular transformation. Oncogene 1999;18:1219-26.
19. Oh S, Song YH, Yim J, Kim TK. Identification of Mad as a repressor of the human telomerase (hTERT) gene. Oncogene
2000;19:1485-90.
20. Cerezo A, Kalthoff H, Schuermann M, Schafer B, Boukamp P. Dual regulation of telomerase activity through c-Myc-dependent
inhibition and alternative splicing of hTERT. J Cell Sci 2002;115:1305-12.
21. Dwyer JM, Liu JP. Ets2 transcription factor, telomerase activity and breast cancer. Clin Exp Pharmacol Physiol 2010;37:83-7.
22. Wu KJ, Grandori C, Amacker M, Simon-Vermot N, Polack A, et al. Direct activation of TERT transcription by c-MYC. Nat Genet
1999;21:220-4.
23. Kanaya T, Kyo S, Hamada K, Takakura M, Kitagawa Y, et al. Adenoviral expression of p53 represses telomerase activity through
down-regulation of human telomerase reverse transcriptase transcription. Clin Cancer Res 2000;6:1239-47.
24. Akincilar SC, Khattar E, Boon PL, Unal B, Fullwood MJ, et al. Long-range chromatin interactions drive mutant TERT promoter
activation. Cancer Discov 2016;6:1276-91.
25. Barthel FP, Wei W, Tang M, Martinez-Ledesma E, Hu X, et al. Systematic analysis of telomere length and somatic alterations in 31
cancer types. Nat Genet 2017;49:349-57.
26. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, et al. Highly recurrent TERT promoter mutations in human melanoma. Science
2013;339:957-9.
27. Alexiadis M, Rowley SM, Chu S, Leung DTH, Stewart CJR, et al. Mutational landscape of ovarian adult granulosa cell tumors from
whole exome and targeted TERT promoter sequencing. Mol Cancer Res 2019;17:177-85.
28. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, et al. TERT promoter mutations occur frequently in gliomas and a subset of
tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 2013;110:6021-6.
29. Koelsche C, Sahm F, Capper D, Reuss D, Sturm D, et al. Distribution of TERT promoter mutations in pediatric and adult tumors of the
nervous system. Acta Neuropathol 2013;126:907-15.
30. Allory Y, Beukers W, Sagrera A, Flandez M, Marques M, et al. Telomerase reverse transcriptase promoter mutations in bladder cancer:
high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol 2014;65:360-6.
31. Borah S, Xi L, Zaug AJ, Powell NM, Dancik GM, et al. Cancer. TERT promoter mutations and telomerase reactivation in urothelial
cancer. Science 2015;347:1006-10.
32. Heidenreich B, Nagore E, Rachakonda PS, Garcia-Casado Z, Requena C, et al. Telomerase reverse transcriptase promoter mutations
in primary cutaneous melanoma. Nat Commun 2014;5:3401.
33. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, et al. TERT promoter mutations in familial and sporadic melanoma. Science
2013;339:959-61.
34. Hurst CD, Platt FM, Knowles MA. Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of
mutations in voided urine. Eur Urol 2014;65:367-9.
35. Remke M, Ramaswamy V, Peacock J, Shih DJ, Koelsche C, et al. TERT promoter mutations are highly recurrent in SHH subgroup
medulloblastoma. Acta Neuropathol 2013;126:917-29.
36. Vinagre J, Almeida A, Populo H, Batista R, Lyra J, et al. Frequency of TERT promoter mutations in human cancers. Nat Commun
2013;4:2185.
37. Wu S, Huang P, Li C, Huang Y, Li X, et al. Telomerase reverse transcriptase gene promoter mutations help discern the origin of
urogenital tumors: a genomic and molecular study. Eur Urol 2014;65:274-7.
38. Campos MA, Macedo S, Fernandes M, Pestana A, Pardal J, et al. TERT promoter mutations are associated with poor prognosis in
cutaneous squamous cell carcinoma. J Am Acad Dermatol 2019;80:660-9.e6.
39. Lee HW, Park TI, Jang SY, Park SY, Park WJ, et al. Clinicopathological characteristics of TERT promoter mutation and telomere
length in hepatocellular carcinoma. Medicine (Baltimore) 2017;96:e5766.